
Alcon Inc.
Alcon
Alcon Inc. is a Swiss eye-care company headquartered in Geneva and founded in 1945. It became an independent public corporation on April 9, 2019, through a 100% spin-off from Novartis AG, and has no controlling shareholder; BlackRock holds 6.5% of voting rights, UBS Fund Management 5.85%, and Vanguard 3.8%. The company employs about 25,000 people, operates in 56 countries, and serves more than 260 million patients and consumers across over 140 countries. It is listed on the SIX Swiss Exchange under ticker ALC and on the NYSE under ALC. For FY2025 it reported revenue of USD 10.401 billion, net income of USD 0.98 billion, total assets of CHF 31.555 billion, and equity of CHF 22.035 billion.
Strengths: Alcon holds the broadest portfolio in ophthalmic devices and ocular pharmaceuticals, spanning surgical equipment (Centurion, Constellation), intraocular lenses (PanOptix, Clareon, Vivity), contact lenses (Dailies Total1, Precision1, Total30, Air Optix), and ocular health products (Systane, Pataday, Rocklatan, Rhopressa). Its 18 major manufacturing and R&D facilities, anchored by the Fort Worth campus, support scale in a category where sterility and precision matter. Revenue grew from USD 8.291 billion in FY2021 to USD 10.401 billion in FY2025, a 25.4% increase that outpaced most device peers. The 2026 acquisition of Neurotech and ENCELTO adds the only FDA-approved treatment for MacTel Type 2, extending the company into retinal pharmaceuticals.
Weaknesses: Profitability is thin relative to revenue: FY2025 net income of USD 0.98 billion represents a 9.4% margin, and FY2024 net income of USD 1.018 billion was slightly lower despite revenue growth. The company faces direct competition from Johnson & Johnson Vision, Bausch + Lomb, Cooper Companies, Carl Zeiss Meditec, and Hoya, limiting pricing power in contact lenses and surgical consumables. Its 2019 spin-off left no controlling shareholder, so strategy is subject to dispersed institutional ownership, with BlackRock alone at 6.5%. Regulatory exposure is concentrated in FDA and EU device approvals, where the ENCELTO and BRYTLY launches depend on post-approval execution.
Read MoreShow Less
Alcon Inc. is a Swiss eye-care company headquartered in Geneva and founded in 1945. It became an independent public corporation on April 9, 2019, through a 100% spin-off from Novartis AG, and has no controlling shareholder; BlackRock holds 6.5% of voting rights, UBS Fund Management 5.85%, and Vanguard 3.8%. The company employs about 25,000 people, operates in 56 countries, and serves more than 260 million patients and consumers across over 140 countries. It is listed on the SIX Swiss Exchange under ticker ALC and on the NYSE under ALC. For FY2025 it reported revenue of USD 10.401 billion, net income of USD 0.98 billion, total assets of CHF 31.555 billion, and equity of CHF 22.035 billion.
Strengths: Alcon holds the broadest portfolio in ophthalmic devices and ocular pharmaceuticals, spanning surgical equipment (Centurion, Constellation), intraocular lenses (PanOptix, Clareon, Vivity), contact lenses (Dailies Total1, Precision1, Total30, Air Optix), and ocular health products (Systane, Pataday, Rocklatan, Rhopressa). Its 18 major manufacturing and R&D facilities, anchored by the Fort Worth campus, support scale in a category where sterility and precision matter. Revenue grew from USD 8.291 billion in FY2021 to USD 10.401 billion in FY2025, a 25.4% increase that outpaced most device peers. The 2026 acquisition of Neurotech and ENCELTO adds the only FDA-approved treatment for MacTel Type 2, extending the company into retinal pharmaceuticals.
Weaknesses: Profitability is thin relative to revenue: FY2025 net income of USD 0.98 billion represents a 9.4% margin, and FY2024 net income of USD 1.018 billion was slightly lower despite revenue growth. The company faces direct competition from Johnson & Johnson Vision, Bausch + Lomb, Cooper Companies, Carl Zeiss Meditec, and Hoya, limiting pricing power in contact lenses and surgical consumables. Its 2019 spin-off left no controlling shareholder, so strategy is subject to dispersed institutional ownership, with BlackRock alone at 6.5%. Regulatory exposure is concentrated in FDA and EU device approvals, where the ENCELTO and BRYTLY launches depend on post-approval execution.
Listed market data
2 Listings · weeklyHistory →- Market cap
- $37.5 B
- Share price
- CHF 62.28
- 1Y change
- +3.4%
- Recent change
- -1.3%
- Since first close
- +24.6%
- Revenue (TTM)
- $10.4 B
11-20
from 2019-04
Financial history
Full market history- 2026-11CHF 62.28$37.5 B+5.4%
- 2026-10CHF 59.10$35.6 B+9.5%
- 2026-09CHF 53.98$32.5 B-7.8%
- 2026-08CHF 58.56$35.2 B+5.7%
- 2026-07CHF 55.38$33.3 B+1.4%
- 2026-06CHF 54.60$32.9 B+4.8%
- 2026-05CHF 52.10$31.4 B-10.5%
- 2026-04CHF 58.22$35 B-1.8%
- 2026-03CHF 59.26$35.7 B-11.4%
- 2026-02CHF 66.86$40.2 B+7.1%
- 2026-01CHF 62.42$37.6 B-1.4%
- 2025-12CHF 63.28$38.1 B—
Ownership & Control
Shareholding as of 2026-11-19- Controlling entity
- Publicly traded Swiss corporation with a broad institutional shareholder base and no controlling shareholder.
- Company type
- Company
- Insiders
- 0.19%
- Institutions
- 66.17%(1,176 holders)
- Free float
- 99.74%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →4 latest headlines- Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growthinvestor.alcon.com2026-11-10
- Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2investor.alcon.com2026-10-20
- FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyesinvestor.alcon.com2026-10-16
- Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Controlinvestor.alcon.com2026-09-03
• Centurion and Constellation systems for cataract and vitreoretinal surgery
• UNITY VCS visualization and UNITY M microscope launched September 2026
• Sold to hospitals and ambulatory surgery centers in 56 direct markets
Intraocular Lenses – implantable lens portfolio
• PanOptix, Clareon, and Vivity premium and standard lenses
• Tied to cataract procedure volume across more than 140 countries
• Competes with Johnson & Johnson Vision and Carl Zeiss Meditec
Surgical Consumables – procedure-linked disposables
• Single-use packs, fluids, and instrumentation for eye surgery
• Recurring revenue tied to installed base of Centurion and Constellation
• Manufactured across 18 major facilities in North America, Europe, and Asia
Contact Lenses – daily and monthly modalities
• Dailies Total1, Precision1, Total30, and Air Optix brands
• Sold through optometrists and retail channels
• Competes with Cooper Companies and Bausch + Lomb
Ocular Health Pharmaceuticals – prescription and OTC eye care
• Systane and Pataday for dry eye and allergy; BRYTLY approved October 2026
• Rocklatan and Rhopressa for glaucoma
• ENCELTO for MacTel Type 2, added through Neurotech acquisition in October 2026
Retinal and Surgical Devices – specialty implants
• Hydrus Microstent for glaucoma surgery
• Neurotech acquisition extends into retinal pharmaceutical delivery
• Fort Worth campus serves as primary R&D hub
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $10.4 B | $980 M |
| 2024 | $9.9 B | $1 B |
| 2023 | $9.5 B | $974 M |
| 2022 | $8.7 B | $335 M |
| 2021 | $8.3 B | $376 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Founded
Employees
Market cap
Factories
Presence
Listing
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.3 T
- Johnson & Johnson (J&J)· $660 B
- Allergan Aesthetics· $517 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $377 B
- Merck Animal Health· $334 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website SIX : ALC
